Advanced Filters
noise

La Mesa, California Clinical Trials

A listing of La Mesa, California clinical trials actively recruiting patient volunteers.

Found 436 clinical trials
D David R Santiago-Dieppa, MD

Assessing Neurocognition After Cerebrovascular Intervention

Decreased blood flow to the brain can cause decreased cognitive function. Carotid disease can result in decreased blood flow to the brain. The investigators seek to assess this relationship prospectively through performing a battery of neurocognitive assessments, collection of serum markers of inflammation, and through neuroimaging at two points before …

18 years of age All Phase N/A
P Pedro Pinto

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.

18 years of age All Phase N/A
J Jeff M Moore, B.S./B.S.

Regional Blood Flow During Peripheral Heating

Blood flow through the popliteal, brachial, and carotid arteries during peripheral heating of the feet

18 - 65 years of age All Phase N/A
S Sherri Brandsen

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the …

12 - 21 years of age All Phase 2
A Amy Stolinski, MPH

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

Hemophilia A (HA) is a genetic bleeding disorder resulting from a deficiency or absence of factor VIII (FVIII), which is necessary in the clotting process. This disorder occurs mostly in males and in severe cases causes frequent bleeding episodes in joints and muscles which can lead to progressive damage that …

6 - 19 years of age All Phase N/A
R Rachel Winograd, RN

Angelman Syndrome Natural History Study

The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.

years of age All Phase N/A

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

The study is a randomized, placebo-controlled design with the opioid antagonist, oral naltrexone. Following random assignment, participants will take 50mg of naltrexone or placebo once a day for 7 days. On days 1 - 7, participants complete reports of their feelings of social connection and mood in order to assess …

18 - 25 years of age All Phase 0
M Mary E McDuffie, RN BSN

Defense and Veterans Center for Integrative Pain Management (DVCIPM) Pain Registry Biobank

This Pain Registry Biobank is a prospective cohort design study whereby data (PASTOR survey, blood and saliva specimens, clinical data) is collected from participants in a longitudinal fashion with continual enrollment.

18 - 80 years of age All Phase N/A
L Lorena Garcia, CRC

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of …

18 years of age All Phase 1/2
S Sherri Brandsen

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

- 31 years of age All Phase 2

Simplify language using AI